Objective
Insulin-dependent diabetes mellitus (IDDM) leads to excess morbidity, reduced life expectancy and costs to the society exceeding 1 million ECU per lifetime of one patient. It is a chronic drain of scarce health care resources and important cause of human suffering. Autoimmune IDDM is preventable in animals but human prevention has been delayed by lack of test subjects who are genetically and immunologically at increased, defined IDDM risk. The demonstration project here outlined will radically change this situation. Its novel technology will find the at-risk subjects for recruitment to the European prevention trials. By installing 4 demonstration centres to the partner countries our intent is to show, by exercise of available best practice, validated in Finland, how prediction technology is used for very early recognition of pre-IDDM. There is a considerable element of novelty in the demonstration in that innovations in gene technology, immunology and time-resolved fluorescence imaging are applied for large-scale screening of general populations. During the course of the demonstration each centre will display and conduct practice in relation to genetic screening and immunological follow-up of relevant birth cohorts.
There will to some extent be specialisation in the centres in that FI will be responsible for the main part of the administration, data handling and training. However, all centres will be able to demonstrate the whole package of descriptions albeit to differing degrees. The existing IDDM prediction practices in the partner states' health care systems will be compared with those, which the demonstration project will newly introduce. Careful attention will be given to the demonstration of the economic advantages of the methodologies on show. Overall the demonstration will transfer and leave to the partner states what is best and validated in the project. The dissemination of knowledge about what can be done in relation to the genetic and immunological prediction of IDDM will, in addition to showing what is possible in clinical centres, develop a publicity machine to inform relevant governmental and non-governmental health care authorities, including the appropriate charities and patient organisations, that there is a new way of attacking an insidious and expensive disease. Preparation of European legal and insurance guidelines regarding gene technology-based disease prediction will also benefit from the extended European use of the demonstration technology.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine endocrinology diabetes
- medical and health sciences basic medicine immunology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
20520 Turku
Finland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.